Literature DB >> 20047481

Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.

S F L van Lelyveld1, M Nijhuis, F Baatz, I Wilting, W M van den Bergh, M Kurowski, D de Jong, A I M Hoepelman, A M J Wensing.   

Abstract

We report the selection of enfuvirtide-resistant human immunodeficiency virus type 1 in cerebrospinal fluid, resulting in subsequent loss of viral suppression in the plasma. This case report emphasizes the potential danger of low-level penetration of entry inhibitors into the central nervous system.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20047481     DOI： 10.1086/649874

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  18 in total

1.  Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.

Authors:  Stefany Moreno-Gamez; Alison L Hill; Daniel I S Rosenbloom; Dmitri A Petrov; Martin A Nowak; Pleuni S Pennings
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

2.  Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.

Authors:  Ting Ting Lee; Gursharan Chana; Paul R Gorry; Anne Ellett; Chad A Bousman; Melissa J Churchill; Lachlan R Gray; Ian P Everall
Journal:  J Neurovirol       Date:  2015-06-03       Impact factor: 2.643

3.  Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics.

Authors:  Sergio M de Almeida; Michelli F Oliveira; Antoine Chaillon; Indianara Rotta; Clea E Ribeiro; Ana Paula de Pereira; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2018-09-07       Impact factor: 2.643

4.  HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Authors:  Arvid Edén; Dietmar Fuchs; Lars Hagberg; Staffan Nilsson; Serena Spudich; Bo Svennerholm; Richard W Price; Magnus Gisslén
Journal:  J Infect Dis       Date:  2010-11-04       Impact factor: 5.226

5.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

6.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Authors:  Michael J Peluso; Francesca Ferretti; Julia Peterson; Evelyn Lee; Dietmar Fuchs; Antonio Boschini; Magnus Gisslén; Nancy Angoff; Richard W Price; Paola Cinque; Serena Spudich
Journal:  AIDS       Date:  2012-09-10       Impact factor: 4.177

7.  Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study.

Authors:  Sergio M de Almeida; Indianara Rotta; Clea E Ribeiro; Michelli F Oliveira; Antoine Chaillon; Ana Paula de Pereira; Ana Paula Cunha; Marise Zonta; Joao França Bents; Sonia M Raboni; Davey Smith; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2017-02-28       Impact factor: 2.643

Review 8.  Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Authors:  Francesca Ferretti; Magnus Gisslen; Paola Cinque; Richard W Price
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

Review 9.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

Review 10.  HIV-associated neurocognitive disorders: perspective on management strategies.

Authors:  Linda Nabha; Lan Duong; Joseph Timpone
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.